Shares in Brussels-listed Onward opened 7% higher at ... up from $6bn in 2022. Onward’s ARC-EX delivers targeted, programmed spinal cord stimulation non-invasively, rather than via implanted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback